FDA frowns on Evolus

Evolus Inc. (NASDAQ:EOLS) said FDA issued a complete response letter for a BLA for prabotulinumtoxinA (DWP-450) to treat adults with glabellar lines (frown lines between the eyebrows). Evolus shed over $90 million in market cap on May 16.

Evolus said the CRL focused solely on CMC process deficiencies. The company plans to resubmit the BLA to FDA within 90 days, and anticipates a spring 2019 launch for DWP-450...